The significant burden of resistance to conventional anticancer treatments in patients with advanced disease has prompted the need to explore alternative therapeutic strategies. The challenge for oncology researchers is to identify a therapy which is selective for tumors with limited toxicity to normal tissue. Engineered bacteria have the unique potential to overcome traditional therapies' limitations by specifically targeting tumors. It has been shown that bacteria are naturally capable of homing to tumors when systemically administered resulting in high levels of replication locally, either external to (non-invasive species) or within tumor cells (pathogens). Pre-clinical and clinical investigations involving bacterial vectors require relevant means of monitoring vector trafficking and levels over time, and development of bacterial-specific real-time imaging modalities are key for successful development of clinical bacterial gene delivery. This review discusses the currently available imaging technologies and the progress to date exploiting these for monitoring of bacterial gene delivery in vivo.
INTRODUCTION
Although the potential anti-cancer effects of acquired bacterial infection have been evident for over 120 years and the presence of bacteria in excised tumors has been noted for over 60 years, 1 it is only in more recent times that the tumor-specific growth of bacteria has been considered for therapeutic purposes. While the precise mechanism(s) behind preferential bacterial tumor colonization remain poorly understood, this phenomenon must relate to unique tumor attributes that separate them from healthy tissues. Factors such as the irregular blood supply; local immune suppression; inflammation; and unique nutrient supply (e.g., purines) in tumors have been proposed to play a role. 2 Bacterial entry into the tumor environment is proposed to be facilitated by the leaky vasculature. Cancer cells are characterized by an aberrantly accelerated metabolism and proliferation leading to an imbalance of oxygen supply and consumption which is a major causative factor of tumor hypoxia. 3 The hypoxic nature of solid tumors enhances the growth of anaerobic and facultatively anaerobic bacteria. In addition, these areas with low oxygen and high interstitial pressure are considered to be an immunological sanctuary, where bacterial clearance mechanisms are greatly inhibited. 4 Necrotic regions are also rich in nutrients favoured by bacteria due to tumor cell turnover. However, tumor selective bacterial colonization now appears to be both bacterial species and tumor origin independent, since aerobic bacteria are also capable of colonising tumors, and even small tumors lacking an anaerobic center are colonised. See Figure 1 for proposed mechanisms.
Invasive bacteria can internalize and replicate within tumor cells, while non-invasive bacteria grow externally to tumor cells, within the tumor micro-environment. 5 The tumor selective growth of bacteria has made them an attractive vehicle for the delivery of reporter genes, therapeutic genes or inhibitory RNA to a tumor for ameliorative or potentially diagnostic purposes. Protocols for the genetic modification of bacterial genomes and the transformation of plasmid DNA containing genes of interest into bacteria are becoming established for an increasing range of species. This allows for the creation of bacteria that (i) directly express therapeutic genes, and/or (ii) efficiently internalize into tumor cells with subsequent therapeutic nucleic acid release for tumor cell expression ('bactofection'). The same bacterium can be engineered to co-express a reporter gene(s) that can be used for in vivo imaging of bacterial localization and spread. Genetic manipulation of bacteria can also be used to create mutants with aberrant nutritional needs or that are attenuated and therefore non-pathogenic.
Bactofection of mammalian cells applies to both active invasion of non-phagocytic mammalian cells (e.g., Tumor cells), and also 'passive' uptake by phagocytic immune cells (DNA vaccination). Vaccination strategies involving bactofection of antigen presenting cells (APC) with defined tumor antigen genes using replication deficient mutants of Salmonella enterica Typhimurium and Listeria monocytogenes have shown significant promise both preclinically and in clinical trials. 6, 7 After oral intake, such bacterial vector cells are phagocytosed by monocytes in the intestine, which differentiate and migrate to lymph nodes and the spleen. Subsequently, the attenuated strains (unable to replicate in hosts) lyse and release plasmid into the cytoplasm of monocytes, followed by expression of the desired antigen and presentation to the immune system. This delivery platform has shown success in tumor models employing various tumor antigens. 8 
BACTERIAL-MEDIATED TUMOR THERAPY
The attractiveness of bacteria as vectors for cancer gene therapy is evidenced by the growing number and range of studies that have employed bacteria. To date, the genera of bacteria that have been exploited as gene delivery vehicles include Salmonella, Escherichia, Listeria, Clostridium and Bifidobacterium. [9] [10] [11] [12] [13] [14] [15] [16] [17] These bacteria can be delivered to the tumor via multiple routes such as intra-tumoral injection, intravenous injection or in certain instances orally. Preclinical studies have shown the ability of different bacterial strains to locally produce therapeutic agents and mediate highly effective and specific therapeutic responses. 5 A wide range of gene therapy strategies exists, aiming at inducing malignant cell death either directly (e.g. using 'suicide' genes) or indirectly, such as cancer immunotherapy approaches based on killing tumor cells through intervention of various effector cells of the immune system. 6 Invasive bacteria can internalize cancer cells and deposit genes within them for host cell expression. In the case of noninvasive bacteria, strains can be engineered to secrete therapeutic proteins locally within the tumor environment, external to tumor cells. 16 This 'cell therapy' approach is suitable for indirectly acting therapeutic strategies such as anti-angiogenesis and immune therapy (see Figure 2) .
Live bacteria were first associated with cancers almost two centuries ago when tumor regression was observed in patients who contracted gas gangrene 18 caused by C. perfringens.
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Clostridia are obligate anaerobic bacteria which proliferate preferentially in regions of solid tumors resulting in tumor regression but also acute toxicity. The application of non-pathogenic Clostridium strains however, has not provided efficient clinical tumor therapy to date. In clinical studies, while C. butyricum M-55 was induced 'liquefaction' (oncolysis) of gliomas, the well oxygenated outer rim of tumors lead to regrowth in all patients. 20 The paucity of molecular tools for this genus has also hindered success at adapting species for gene delivery.
Genetically engineered strains of Salmonella have also been proposed for tumor selective therapy. Salmonella are Gramnegative motile bacteria that have potential to grow in both oxygenated and hypoxic tumor areas. S. Typhimurium has been genetically engineered to produce a variety of therapeutic agents, with success in animal models, accomplishing relatively tumorspecific therapeutic gene expression, reviewed by Chorobik et al.
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Despite the preferential tumor colonization following the administration of attenuated Salmonella to tumor-bearing animals normal tissues are also colonised transiently and to a lesser extent. 16 A safety-attenuated strain of S. Typhimurium designated VNP20029 has been examined in several clinical trials. 22 The preclinical success of Salmonella has not, however, translated into human studies, and clinical trials have demonstrated tumor colonization in only a low proportion of patient tumors. 23 This is most likely as a result of the maximum tolerable dose exceeding the therapeutic dose, resulting in a poor therapeutic window. The only established, licenced cancer therapy employing bacteria is Bacillus Calmette-Gué rin (BCG), an attenuated Mycobacterium bovis strain which was successfully used by Morales, Eidinger and Bruce in 1976 for the treatment of superficial bladder cancer. 24 BCG has become the treatment of choice for high risk, superficial bladder cancer in most countries, with an increasing rate of treating approximately one million patients per year. 25 While the benefits of using bacteria as vectors for cancer gene therapy are abundantly clear, there are some disadvantages associated with their use in cancer treatment. As with all vector strategies, balance between efficacy and safety is key. In terms of safety, despite the use of safety-attenuated bacterial strains in gene therapy studies employing pathogenic species, the possibility of inducing an immune-mediated toxic response in the host following bacterial administration remains a concern. Therefore interest in prokaryote-based approaches to cancer therapy has re-emerged with the discovery of non-pathogenic strains that specifically and preferentially target solid tumors. This method has drawn further attention with the development of techniques to genetically modify the bacteria, thereby enabling the expression of anti-cancer therapeutic genes in these hosts. 26 Numerous publications provide convincing evidence that genera of bacteria including Bifidobacterium and commensal Escherichia coli have potential in cancer therapy. 9, 10, 12, 16, [27] [28] [29] [30] This vector class compares favorably with other vectors in terms of key attributes such as safety, ease of manipulation, and production. While nonpathogenic bacteria have yet to enter clinical trial in the context of tumor targeting vectors, existing knowledge strongly indicates their suitability as a vector system for clinical use.
The inconclusive outcomes to date from bacterial gene therapy strategies in Phase I/II clinical trials has hindered the progression of this concept. 20, 31 For gene therapy in general, a paucity of technologies to monitor events post vector administration to patients represents a block in clinical progression. 32 Indeed, in response to the first gene therapy death, the NIH Recombinant DNA Advisory Committee (RAC) called for better assays to monitor gene delivery. 33 As the field of bacterial gene therapy develops, it is becoming clear that the ability to image bacteria in vivo following administration is essential. Therefore, in order to determine the location and spread of bacteria within the treated host, the bacteria must be amenable to one of the rapidly evolving modes of imaging that are available to researchers today. Unlike other vector strategies, humans feature a 'background' of indigenous bacteria (GIT, oral and genital cavities, skin), and therefore, high specificity for the vector of interest is required, be it from introduced reporter genes, or strain-specific probes.
IN VIVO IMAGING
The evolution of novel biological imaging techniques has played a major role in the development of modern medicine. Advances in the specificity and sensitivity of imaging devices has led to vast improvements in the diagnosis and treatment of disease as well as the development of drugs and the study of biological processes in vivo. The perpetual aim of in vivo imaging is to achieve increased sensitivity and resolution. A number of clinical molecular imaging strategies are available which are suited to preclinical studies of bacterial gene therapy, primarily Positron Emission Tomography (PET) and microPET. A more readily accessible technology available to standard research laboratories is Optical Imaging (OI) which is based on the detection and quantification of bioluminescent or fluorescent light from a subject, through use of a cooled charged coupled device (CCD) camera. The relevant merits and obstacles to these and other methodologies in the context of bacterial gene therapy of cancer are discussed in this review.
OPTICAL IMAGING
Optical imaging is a highly sensitive, nontoxic technique based on the detection of visible light, produced by luciferase enzymecatalyzed reactions (bioluminescence) or by excitation of fluorescent molecules, using sensitive photon detectors. Although the light emitted may be dim, it is detectable externally using sensitive photon detectors such as those based on cooled, or intensified CCD cameras, mounted within light-tight specimen chambers. The development of bioluminescent/fluorescent microorganisms allows the real-time non-invasive detection of bacteria within intact living animals. As light passes through a range of tissue types, it is possible to observe and quantify the spatial and temporal distribution of light production from within tumors or other tissue. Multiple imaging of the same animal throughout an experiment allows the progression of bacterial colonization to be followed with accuracy, reducing the number of animals required to yield statistically meaningful data.
BioLuminescence imaging (BLI)
Bioluminescence involves the release of light energy following a chemical reaction catalyzed by a luciferase enzyme. 34 Luciferases generate visible light of a specific wavelength through the oxidation of their specific substrates. Unlike fluorescence, no external light source is necessary. Luciferase proteins have been isolated from a variety of insects, marine organisms and prokaryotes. 35 Some of the most common luciferases are derived from the North American firefly Photinus pyralis (FLuc), the sea pansy Renilla luciferase (RLuc), the marine copepod Gaussia princeps luciferase, (GLuc) and the bacterial luciferase gene cassette (lux). 8, 17, [36] [37] [38] Both RLuc and GLuc metabolize coelenterazine to produce visible light predominately in the blue-green spectrum which is not optimal for whole body imaging as light in this range is efficiently absorbed by living tissue. 39 Red-shifted RLuc variants have been developed which improve penetration of light in biological matrices. 40 The most significant disadvantage to the in vivo application of these reporters is the poor half-life of coelenterazine in animal systems; however variants with improved longevity in animals are being developed. 41 To date GLuc has been successfully expressed in Mycobacterium smegmatis and used in whole animal imaging modalities. S. Typhimurium engineered to express a variant of Rluc gene (RLuc8), under the control of the E. coli arabinose operon promoter (P BAD ) have been imaged in murine tumors, with the added advantage of demonstrating 'remote control' of bacterial gene expression. 42 Notwithstanding the above luciferase/substrate combinations, the bacterial-native lux system represents the mainstay of current in vivo bacterial OI. 43 The luxAB genes isolated from Vibrio harveyi 44 and Photorhabdus luminescens (formerly Xenorhabdus luminescens), amongst others, have since been combined with all genes required for enzyme and substrate transcribed from a single cassette luxCDABE. 45 This non-invasive imaging system allows for qualitative and quantitative analysis of the localization of bioluminescent bacteria in small animal models. It is important to note that bioluminescence from lux-and Luc-expressing microorganisms is related to an organism's metabolic activity. This is due to the reliance of the luciferases on microbial metabolites, mainly FMNH 2 and ATP, respectively. This is exemplified by the decrease in luminescence that has been observed when many luxexpressing bacterial species, such as Bifidobacterium, 38 enter stationary phase during in vitro growth. [46] [47] [48] Bioluminescent bacteria have been used extensively to study a diverse range of biological processes such as infection, 49 quorum sensing 50 and gene expression. 51 However, the employment of luciferase or lux tagged bacterial strains as gene delivery vehicles for the treatment of cancer is an emerging field. 52, 53 A powerful potential diagnostic approach involves the use of genetically modified light-emitting bacteria to visualize their colonization of tumors (Figure 3) , thereby revealing the location of tumors based on light emission.
Fluorescence imaging Another non-invasive imaging technique that has been successfully utilized to visualize bacterial vectors in cancer gene therapy is fluorescence imaging. In fluorescence imaging, an external light source excites a fluorophore [fluorescent protein (FP) or dye] and the transferred light energy is emitted at a different wavelength when the fluorophore returns back to its ground state. The excitation of the fluorophores by filtered light of a defined wavelength results in the emission of a fluorescent signal. This low energy, shifted wavelength light signal can be identified and quantified both in vitro and in vivo without the requirement for cell/animal sacrifice. The high level of autofluorescence and visible light absorption associated with in vivo imaging of fluorophores in the green spectrum greatly limits the tissue depth from which a clear fluorescent signal can be obtained. 54, 55 However, the development of near-infrared (NIR) probes has allowed the in vivo analysis of fluorescence to become practical. 56 NIR probes reduce the level of background signal by increasing the signal-to-noise ratio and therefore facilitates fluorescent imaging at greater depths. 57 For a fluorescent marker to be successfully used for optical imaging, it has to fulfill several criteria including suitable excitation and emission wavelengths, photostability, brightness and maturation speed. [58] [59] [60] Historically, the most commonly used fluorescent probe for the detection of bacterial vectors is the green fluorescent protein (GFP) or its derivatives. GFP is an isolate from the jellyfish Aequorea Victoria. A number of studies have recently described imaging of GFP-expressing bacteria in live bacterial-infected animals. 11, 61, 62 Such studies use fluorescent imaging for monitoring the infection progression over time and illustrate the spatial-temporal behavior of the process. Bacteria expressing the GFP variants are sufficiently bright as to be clearly visible from outside the infected animal and the increasing levels recorded using a CCD camera. An auxotrophic strain of S. Typhimurium A1 expressing GFP which caused nuclear destruction in vitro and tumor inhibition and regression of xenografts has been visualized in vivo by whole-body imaging. 62 The sensitivity of GFP fluorescence, in conjunction with the R. reniformis luciferase (RUC), has been exploited to study E. coli, S. Typhimurium and Vibrio cholera colonization of tumors in live animals. 52 The sensitivity of GFP imaging was also used to facilitate the identification of metastasized tumors where strong fluorescence demonstrates intra-tumoural growth of bacteria at primary and secondary tumor sites. 63 Fluorescence imaging is also valuable for fine-detail postmortem histological study of bacterial localization. 9 To date, almost all the published reports of fluorescent imaging for bacteria utilize GFP, despite its unsuitable excitation and emission wavelengths for tissue penetration. However, the relative explosion in the number of red-shifted FPs developed in recent years should see this exciting field begin to flourish.
Instrumentation for OI
The minute amount of light emitted by optical reporters is detected using a CCD camera which is generally kept cooled to À 90 1C or below. 64 Depending on the imaging strategy, optical filters can select for both excitation and emission wavelengths as required. Although filters are primarily used for fluorescence imaging, they can also distinguish between luminescent reporter signals and for determining the depth of a luminescent source within a subject. Both 2D and more recently 3D OI tomography instrumentation and software (e.g., IVIS Spectrum-Caliper; PhotonIMAGER-Biospace Lab) are available that provide quantitative information with improved spatial resolution. 65 An overview of currently available instrumentation is reviewed elsewhere. 66 Overall, the development of more affordable or more powerful instrumentation, in combination with other imaging methods such as X-ray and micro-CT is rapidly advancing the OI field. 67 Engineering bacteria to express reporter genes A caveat to the exploitation of bacterial reporter systems is the recalcitrance of certain species to genetic manipulation. The engineering technology currently available for tagging of different species has dictated what bacterial strains have been reported in the context of OI to date. The suitability of OI for bacterial studies is dependent on the ability to genetically modify the bacterial strain in question to stably carry and express the reporter gene (e.g., lux or a FP gene), and also the activity of the reporter system in that strain. Even in currently genetically tractable strains, the activity of the lux system varies dramatically between bacterial species. 43 Some considerations for improving bacterial reporter gene expression are discussed below.
Stable gene expression. The integration of reporter genes in a bacterial genome is preferable over episomal plasmid-based expression to ensure stable and homogenous expression levels. Importantly, this also provides the opportunity to remove the need for antibiotic selection generally required to maintain plasmids which would be unavailable in vivo, and represents an important regulatory consideration in terms of clinical application. Alternative methods of maintaining episomal plasmids in the Lux-labeled (i) E. coli K12 MG1655 or (ii) B. breve UCC2003 were administered via tail vein to either athymic or Balb/c mice bearing subcutaneous FaDu hypopharyngeal carcinoma or CT26 colorectal carcinoma respectively. Lux signal was detected by 2D in vivo BLI specifically in tumors of mice 3-14 days post IV-administration. 2D BLI is also useful for imaging DNA vaccine delivery using Salmonella as a vector in the gastrointestinal tract of mice. Trafficking of S. Typhimurium SL7207 in the initial 10 h after gavage feeding was monitored using a bacterial lux expressing strain and BLI. A representative C57 BL/6 mouse gavage fed SL7207 is illustrated in (iii). A specific antitumour immune response was generated in a murine model of prostate cancer by oral administration of salmonellae containing a plasmid coding for murine prostate stem cell antigen (PSCA). 8 (b) Bacterial mediated transfer of plasmid DNA to tumor cells (bactofection) using Listeria monocytogenes. The ability to use L. monocytogenes to deliver genes to tumors in vivo was assessed using the eukaryotic cell-specific CMV promoter to express FLuc reporter gene. 10 6 L. monocytogenes/FLuc was intratumourally administered to athymic mice harboring subcutaneous MCF-7 tumors. Mammalian cell expressed FLuc luminescence was observed specifically in tumors. 17 absence of antibiotic selection have also been developed. For example, strains of E. coli rendered metabolically dependent on diaminopimelic acid (DPI) have been generated, permitting maintenance of plasmids featuring DPI-producing genes as plasmid loss lead to bacterial cell death. 68, 69 Transposon, 46, 70 transducing bacteriophages, 42 temperature sensitive vectors 71 and bacteriophage integrase systems [72] [73] [74] have been developed to integrate genes into the chromosomes of selected bacteria. However, it is important to stress that the maintenance and expression of high levels of recombinant DNA may place an unwelcome metabolic burden microorganisms. Indeed, a number of researchers have described attenuation in lux-and GFPexpressing strains. 47, [75] [76] [77] Maximizing reporter expression. Bacterial reporter gene expression is exquisitely dependent on transcriptional and translational signals. The choice of promoter is vital for optimizing reporter levels and should be assessed on an individual strain basis. The codon usage of the particular organism of interest is also an important consideration. The sequence of the lux genes is AT-rich (469%) and as a result they are not always expressed efficiently in high-GC bacteria such as Streptomyces coelicolor. A synthetic lux operon lacking TTA codons was constructed and validated for S. coelicolor. 78 Furthermore, codon optimizing the firefly luciferase for M. tuberculosis resulted in a 30-fold increase in signal. 74 However codon optimization may have unforeseen effects; the lux operon codon optimized for M. tuberculosis was found to be nonfunctional 74 reported to be as a result of secondary DNA structures which impede translation.
Increasing cofactor availability. For bacteria expressing the lux operon, it is possible that the availability of aldehyde and FMNH 2 are limiting factors. The insertion of an extra promoter in front of luxCDE to boost substrate synthesis resulted in a six-fold higher lux signal in M. smegmatis 74 and S. aureus. 79 In yeast, co-expression of luxAB together with an frp gene which encodes an NADPH-FMN oxidoreductase from V. harveyi, led to a 100-fold increase in luminescence. 80 This strategy has also been applied to bacteria and the frp from V. harveyi was cloned in reporter gene constructs for use in S. aureus. However in this case inclusion of frp was detrimental and resulted in no transformants 79 potentially due to the generation of superoxide (O 2 À ) from the auto-oxidation of flavoproteins. 79 Dual bioluminescent/fluorescent labeling of microorganisms In genetically accessible strains of bacteria the dual labeling of strains with both fluorescent and bioluminescent reporter genes combines the strengths of both systems and reduces the effect of individual cofactor requirements of FPs and luciferases. Tagging strains with a luciferase in tandem with GFP has allowed the discrimination between microbial counts (by fluorescence) and metabolic activity (by bioluminescence). [81] [82] [83] Furthermore, fluorescence labeling allows samples to be analyzed by fluorescence microscopy and flow cytometry in addition to OI. Importantly, this means that more data can be gathered using fewer experimental animals while also bridging the gulf between the macroscopic and microscopic levels of resolution, that is, individual microorganisms at one end of the imaging spectrum and the detection of mass populations in specific niches in the living animal at the other. 84 Applications of OI reporter genes Early demonstrations of the tumor targeting capabilities of lux expressing bacteria not only provided clear evidence for selective in vivo growth and replication of bacteria within tumors, but also importantly showed that whole body imaging of animals colonised by bioluminescent bacteria could be a useful method in the study of bacterial gene therapy of cancer. A model organism, E. coli K12 MG1655, has been demonstrated to specifically colonize a wide array of tumor xenografts, including metastases, following IV administration. 68, 69 This has also been supported by findings with other bacterial species such as bifidobacteria. 38 The use of co-imaging techniques to simultaneously visualize luciferase and lux signals in vivo has been used to great effect to demonstrate the clustered growth pattern of lux expressing bacteria in different tumor models 9 (see Figure 4) . The administration of lux-tagged commensal bacteria to mice harboring luciferase tagged tumors facilitates the generation of 3D diffuse optical tomography displaying the exact distribution of the bacteria within the tumor mass, in relation to viable tumor regions and vascular supply [through computed tomography (CT) imaging]. While non-invasive bacteria such as B. breve and E. coli MG1655 are not amenable to strategies requiring transfection of tumor cells, their ability to selectively grow within the tumor microenvironment makes them ideal candidates for 'cellular therapy' of cancer, i.e., bacterial production of therapeutics within the tumor stroma.
OI alternative approaches-bacterial-specific probes Gene-based reporter technology is not applicable to all bacterial strains. The development of a suitable genetic reporter construct can involve substantial resource commitments, and differences in subsequent reporter gene expression between strains hinders applications. Therefore a number of groups have explored alternative strategies using synthetic probes in combination with OI to image bacteria in vivo. Identification of substrates or metabolites specific to bacteria and not mammalian cells permits exploitation for imaging through addition of an imaging moiety.
Near-infrared probes. The use of an injectable NIR probe consisting of a bacterial affinity group conjugated to an NIR dye is recently demonstrating success. 85, 86 Maltodextrin-based optical imaging probes have been shown to successfully detect small numbers of bacteria in vivo with very high specificity and selectivity due to the fact that maltodextrin transporter is unique to bacteria. 87 A further advantage to this strategy is that the lumen of intestinal tissues and the skin are not permeable to glucose oligomers, and therefore MDPs delivered systemically should not be internalized by the resident bacterial microflora. Similarly, bis-zinc(II)-dicolylamide ligands have high affinity for the anionic phospholipids and other molecules residing in bacteria. 86 Xenolight RediJect probe sold by Caliper is a NIR fluorescent agent for in vivo detection of bacteria targeting the anionic phospholipids of bacterial cell membranes. The potential to adapt these technologies to image bacteria colonising tumors is exciting; however this approach may only be applicable to subcutaneous surface tumors. Imaging of bacteria in deeper tissues with higher background fluorescence requires colonization numbers of 10 8 or more in a defined space.
Quantum dots. In recent years, quantum dots (QDs) have received some attention as probes for OI, especially in cancer research. QDs are small fluorescent nanocrystals made of inorganic semiconductor materials. They are extremely photostable with wide excitation and narrow emission spectra and as their emission wavelength depends on their size they can be manufactured to suit the requirement. However, for bacterial gene therapy applications the size of the QD can inhibit binding of the probe to its target on the bacterial surface. 88 Although autofluorescence is decreased with NIR emission wavelengths, tissue absorption and scattering still impede the amount of excitation light that reaches the fluorophore. To address this 'self-illuminating' QDs have been developed which couple QDs with the Renilla luciferase. 89 By completely eliminating the need for excitation light, this very elegant approach could be refined by combining different luciferases with QDs of different wavelengths. 84 Overall, such strategies represent an exciting avenue for imaging bacteria within all tissue types which is ideally suited to cancer gene therapy-related applications.
POSITRON EMISSION TOMOGRAPHY
While fluorescent and luciferase based imaging is effective in small animal models, these imaging techniques have not, as yet, been adapted for routine clinical use. It is in this respect that PET is seen as a vital imaging modality in the translation of cancer gene therapy from the lab to the clinic. 90 PET exploits the emission of pairs of g-rays from positron emitting radionuclides to create quantitative, 3D images, of in vivo biological processes. 91 Molecular probes labeled with positron-emitting isotopes are used to detect biologically active molecules, as a result of the target-dependent sequestration of the systemically administered positron-emitting probes. 92 While one of the most commonly utilized PET probes-fluorodeoxygluxose labeled with fluorine, 18 also known as [
18 F] FDG-has previously been used as a radiotracer to image bacteria in vivo, it is the use of thymidine kinase (TK) substrates that has been appropriated to greatest effect in bacterial gene therapy studies. These TK substrates become trapped within tumor cells that have been colonised by bacteria allowing for quantitation of intra-tumoral bacteria as well as visualization of the tumor in vivo. Exploiting endogenous bacterial activity for imaging The development of imaging techniques and therapies that rely solely on the endogenous activities of bacteria present fewer regulatory hurdles than vectors featuring genetic modifications. The endogenous bacterial TK activity of several strains including E. coli, C. novyi, S. aureus, and Enterococcus faecalis has been exploited to monitor their location and tumor targeting activity. 95 The bacteria can be selectively imaged in experimentally-infected mice using exogenously administered [ 125 I]FIAU, a nucleoside analog substrate for microbial TK. 96 The TK enzyme phosphorylates FIAU, leading to accumulation within the bacteria. Since FIAU is a poor substrate for mammalian TK, the radiotracer selectively labels bacteria. The bacteria can therefore be imaged in situ using PET or single photon emission computed tomography (SPECT) in conjunction with CT. Since radio-pharmaceutical based imaging provides a comprehensive 3D assessment of the whole tumor it correlates well with colonization levels.
A strategy termed sequential reporter-enzyme luminescence has been described recently, which combines luciferase-expressing bacteria with a b-lactamase-cleavable substrate. 97 Bluco is a 'caged' luciferin, which is released by bacterial b-lactamase hydrolysis for reacting with luciferase. 98 Tumor targeting 
MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging (MRI) has a number of important advantages over other non-invasive imaging modalities, described in detail by Waerzeggers et al. 100 but are summarized as follows; (i) it has relatively high three-dimensional spatial resolution when compared with PET (ii) it has very good sample penetration in multiple imaging planes, (iii) it has the ability to measure more than one physiological parameter using different radiofrequency pulse sequences, (iv) it has no risk of ionizing radiation and (v) it is already widely used in the clinic. 100 A drawback is its low sensitivity: approximately micromolar concentrations of an imaging probe can be detected within a given voxel (10 À 3 -10 À 5 mol/l) which is three to six orders of magnitude lower than the sensitivity of optical imaging for detection of fluorochromes in vivo. 101 Benoit et al. 102 exploited the innate physiology of magnetotactic bacteria to target tumors in mice and provide positive contrast for visualization using MRI. The ability of Magnetospirillum magneticum AMB-1 to confer positive MRI contrast was determined both in vitro and in vivo. 102 The strain was administered to tumor bearing mice either intra-tumorally or intravenously and tumor targeting was confirmed using a multiple of approaches including 64 Cu-labeled bacteria. Significantly M. magneticum with small magnetite particles generate T1-weighted positive contrast, enhancing in vivo visualization by MRI. Ferritins are ubiquitous iron storage proteins and recent studies have shown that human ferritin can be used as a reporter of gene expression for MRI. 103 Bacteria also encode three classes of ferritintype molecules which Hill et al. 104 have recently investigated for their potential as MRI reporter genes. 104 Tumor specific induction of bacterioferritin-expression in colonised murine tumors resulted in contrast changes within the tumors. However, such research on MR imaging genes is still in its infancy and with the exception of the previously discussed studies, its ability to complement bacterial gene therapy imaging is currently limited.
COMBINED IMAGING AND THERAPY
Magnetic resonance spectroscopy (MRS) complements MRI as a non-invasive means for the characterization of tissue. MRS has been used for quantitative non-invasive imaging of tumors expressing cytosine deaminase as a combined reporter and therapeutic gene. 105 Stegman et al. 105 exploited cDNA encoding for yeast cytosine deaminase (CD) in combination with the prodrug 5-fluorocytosine (5-FC). The yCD-catalyzed conversion of 5-FC to the chemotherapeutic agent (5-FU) was quantified in vivo using 19 F MRS. Similar prodrug therapy approaches using bacterial expressed CD exist in the literature. VNP20009 and its derivative TAPET-CD (which expresses the E. coli CD) have been investigated in Phase 1 clinical trials in cancer patients. Pre-clinical studies with the commensal Bifidobacterium have also been conducted. The 'Bifidobacterial Selective Targeting' BEST 10,106 strategy exploits B. longum 105-A containing pBLES100-S-eCD plasmid with CD under the control of the hup gene promoter of B. longum.
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B. longum selectively produces CD in hypoxic mammary tumor tissues in rats, and converts 5-FC into 5-FU in vivo. [108] [109] [110] This system could be significantly improved by combination with MR imaging technology.
Thymidine Kinase is another example of a gene therapy approach which combines both therapeutic and reporter activity simultaneously. The most commonly used TK for gene therapy studies is HSV-TK in combination with an acycloguanosine such as ganciclovir which has been tested in a series of pre-clinical and clinical trials in a wide range of cancer types. 111, 112 The potential exists to improve this study by combining it with multi-modality imaging techniques such as SPECT, PET or MRI. Combined application of the imaging modalities and imaging probes will maximize the diagnostic and therapeutic potential of bacterial gene therapy and achieve a targeted regime for cancer therapy with minimal off-target effects.
CONCLUSIONS AND FUTURE PERSPECTIVES
A growing number of studies, as discussed in this review, have reported the successful targeting and treatment of murine tumors by bacteria. However, numerous challenges remain before these vectors can be routinely applied in the clinic, including identifying the targeting mechanism as well as addressing concerns regarding toxicity and genetic instability. The potential for the vector to cause toxicity in the host as well as the genetic instability of any exogenous genes will need to be addressed on an individual strain basis but may be circumvented through the use of non-pathogenic strains or exploiting endogenous genes for prodrug activation. The challenge of successful targeting of the bacterial vector to the tumor is a complex issue. The ideal application of the vector would target not only the primary tumor but also metastases at distal sites without affecting healthy tissue. In order to demonstrate this targeting, the ability to image the vector in patients is essential.
Each imaging modality has inherent strengths and weaknesses, with none fulfilling all purposes. Nuclear medicine imaging modalities such as PET are highly sensitive but suffer from poor spatial resolution. 100 MRI has the highest image resolution, but sensitivity is less than nuclear techniques. 34 FP detection has shown some success at preclinical levels however high background levels and poor tissue penetration of both excitation and emission waves restrict efficacy. BLI reporting systems display fewer drawbacks and autoluminescence is almost non-existent permitting much higher sensitivity and specificity than fluorescence in vivo. However there are some obvious limitations to OI such as light scattering and spatial resolution which is depth dependent.
113 3D optical tomography systems have improved the resolution and the increasing availability of defined bandwidth filters for capturing photonic signals, and improvements in spectral unmixing algorithms to differentiate between signals with different emission spectra, opens up exciting new avenues for bacterial imaging in vivo. However the OI technology is currently limited to small animals or surface tumors.
The inherent disadvantages associated with each modality means none are perfectly suited to advance the concept of bacterial gene therapy of cancer alone. However, the potential to co-register optical-imaging data with other technologies such as MRI, PET or even SPECT, X-ray and CT is an exciting development. A variety of factors determine the choice of specific imaging system, some of them are the imaging requirements (single or repeated), the proposed use (animal or human) and spatial requirements (tissue depth). Combination imaging should allow each modality to bring its unique advantages to the fore, while providing complementary information. The ability to monitor bacterial colonization dynamics by optical imaging or exploiting endogenous/exogenous genes in combination with an imaging technology while simultaneously recording the resultant changes in host physiology and anatomy using other imaging modalities,
